-+ 0.00%
-+ 0.00%
-+ 0.00%

IN8bio presents Phase I INB-200 glioblastoma study data at ASCO 2026

PUBT·05/06/2026 12:03:15
Listen to the news
IN8bio presents Phase I INB-200 glioblastoma study data at ASCO 2026
  • IN8bio scheduled new clinical data from its Phase I INB-200 study of gene-modified autologous gamma-delta T cells in newly diagnosed glioblastoma for presentation at ASCO on June 1, 2026.
  • Data were not presented in this announcement; release is positioned as an update on progress from early-stage testing and clinical characterization.
  • Company also flagged translational findings that it says support previously observed survival benefits in DeltEx DRI-treated glioblastoma patients, with a broader pipeline update set for its May 21, 2026 R&D Day.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060800PRIMZONEFULLFEED9713468) on May 06, 2026, and is solely responsible for the information contained therein.